Synairgen Share News (SNG)

Synairgen Swings To Profit On Transformational AstraZeneca Deal

Synairgen raises funds to develop AstraZeneca drug

Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is

UK MORNING BRIEFING: William Hill Promotes From Within

Synairgen Raises GBP5.3 Million In Share Placing At 50 Pence

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff

MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions

LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.

Read more

TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014

LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more

London open: Mining stocks pull FTSE 100 lower ahead of data

- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound

AstraZeneca signs licence deal with Synairgen

British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de

UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen

LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.

AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology

AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen

LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections

Synairgen Pretax Loss Narrows On Expenses

LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye

Synairgen Jumps As It Raises Cash While Progressing Licensing Talks

LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery

UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool

LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.

Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi

Synairgen reports 'significant progress'

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote